Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Low Stage Lymphocyte Predominant Hodgkin Disease in Children
NCT00107198Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Mar 2006
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin, vincristine sulfate liposome injection, prednisone and cyclophosphamide in lymphocyte-rich classical Hodgkin lymphoma (LR-cHL), sponsored by Children's Oncology Group. Primary endpoint: Failure-free Survival at 5 years. Started Mar 2006; status: completed.
02
Drugs
pegylated liposomal doxorubicinvincristine sulfate liposome injectionprednisonecyclophosphamide
03
Conditions
lymphocyte-rich classical Hodgkin lymphoma (LR-cHL)
Beyond the preview
Go deeper on NCT00107198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00107198.